Trellus Health, a digital health solutions provider specializing in inflammatory bowel disease (IBD), has announced a collaboration with Johnson & Johnson Health Care Systems Inc. This partnership aims to enhance care for IBD patients in the United States by integrating Trellus Health’s platform, Trellus Elevate™, into patient support programs for those prescribed a Johnson & Johnson therapy.The one-year pilot program will provide patients with access to Trellus Elevate™, a platform designed to offer a holistic approach to patient care by combining data analytics with resilience-driven health programs. This initiative seeks to address both the psychological and physiological aspects of IBD,…
Author: Abhay Panchal
In 2024, major drug approvals in gastroenterology and hepatology included FDA and EMA authorizations of biosimilars to Stelara and Humira for Crohn’s disease and ulcerative colitis, enhancing treatment options for both adult and pediatric patients. Additionally, the FDA approved Hercessi, a biosimilar to Herceptin, for treating HER2-overexpressing metastatic gastric and gastro-esophageal junction adenocarcinoma. These advancements signify strides in expanding therapeutic accessibility and personalized care. Could this trend mark the beginning of a transformative era in GI and hepatology treatments?
Eli Lilly’s Omvoh® (mirikizumab-mkrz) has received FDA approval for treating moderately to severely active Crohn’s disease in adults, marking its second indication for inflammatory bowel disease (IBD). Results from the pivotal Phase 3 VIVID-1 trial demonstrated significant improvement in clinical remission (53%) and endoscopic response (46%) at one year, with nearly 90% maintaining remission after two years in an open-label extension. Omvoh targets the IL-23p19 protein to reduce inflammation, offering long-term disease control even for patients unresponsive to other therapies. Could Omvoh redefine care for Crohn’s and ulcerative colitis globally?
Fractyl Health announced promising early results from the REVEAL-1 cohort of the REMAIN-1 study, showing weight maintenance one month after GLP-1 drug discontinuation and the Revita procedure. This aligns with prior findings and underscores Revita’s potential in addressing post-GLP-1 weight regain challenges. Strong enrollment progress highlights significant demand for alternatives to chronic GLP-1 therapies, with mid-point analysis expected in Q2 2025. Revita, a breakthrough device targeting gut-driven metabolic disease, represents a promising step toward durable weight maintenance solutions. Could this mark the start of a new era in obesity and diabetes care?
Advancements in inflammatory bowel disease (IBD) care, including wearable biosensors, at-home testing, and oral medications, promise to revolutionize disease management, offering personalized, efficient, and proactive treatment options. UChicago Medicine IBD Center is at the forefront, exploring technologies like inflammation-detecting wearables, sweat sensors, and stool analysis apps.
This comprehensive review by the AGA explores best practices in endoscopic enteral access, aiming to guide gastroenterologists in optimizing patient care. It discusses the indications, preprocedural considerations, techniques, and complications of enteral tube placements like NG, NJ, PEG, PEGJ, and DPEJ, emphasizing their role in delivering nutrition, medications, or decompression in patients unable to maintain adequate oral intake. Highlighting a multidisciplinary approach and careful tube selection based on patient anatomy and needs, the article underscores the importance of informed consent, infection control, and postprocedural care. Familiarity with these methods is vital for mitigating malnutrition and enhancing patient outcomes.
In 2024, pivotal advancements in gastrointestinal cancer research have emerged, spotlighting innovative treatments and potential new standards of care. Highlights include the promising efficacy of sotorasib plus panitumumab for KRAS-mutant metastatic colorectal cancer, and the success of novel combinations like durvalumab with bevacizumab and TACE for hepatocellular carcinoma.
Rob Greer, founder of SovDoc, dives into the evolving role of private equity in healthcare, offering invaluable insights for surgeons navigating growth or potential sales. From breaking down the significance of EBITDA in practice valuation to leveraging AI and operational tweaks for financial growth, Rob shares practical strategies tailored to clinicians.
The UK Biobank Pharma Proteomics Project, the largest study of circulating proteins, is set to revolutionize healthcare by enabling earlier detection of diseases like cancer, dementia, and autoimmune conditions through blood tests. Backed by a consortium of pharma giants like Pfizer and AstraZeneca, the project will analyze protein levels from 600,000 blood samples, providing insights into how genes, lifestyle, and environment influence disease progression. Early findings reveal proteins linked to diseases years before diagnosis and the potential to repurpose existing drugs for new treatments.
Novo Nordisk has expanded its collaboration with Valo Health, a Flagship Pioneering company, to leverage artificial intelligence in drug discovery for obesity and diabetes. The partnership aims to accelerate the identification and development of novel therapies by combining Novo Nordisk’s expertise in metabolic diseases with Valo Health’s AI-driven platform. This move reflects the growing trend of integrating AI in pharmaceutical research to tackle complex conditions. Could this be the breakthrough needed to transform diabetes and obesity management?